Who are Lithium (LI)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lithobid, Tegretol, CARBAMAZEPINE, Valproic acid, sodium salt, Depakote (divalproate), sodium valproate with Clozapine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lithium-li.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Lithium (LI) — Competitive Intelligence Brief

Lithium (LI) (Lithium (LI)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mood stabilizer. Area: Psychiatry.

marketed Mood stabilizer Inositol monophosphatase, GSK-3 (glycogen synthase kinase-3) Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Lithium (LI) (Lithium (LI)) — Weill Medical College of Cornell University. Lithium modulates intracellular signaling pathways, particularly inhibiting inositol monophosphatase and glycogen synthase kinase-3 (GSK-3), which alters neurotransmitter activity and neuroprotective processes in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lithium (LI) TARGET	Lithium (LI)	Weill Medical College of Cornell University	marketed	Mood stabilizer	Inositol monophosphatase, GSK-3 (glycogen synthase kinase-3)
Lithobid	lithium carbonate	Generic (multiple manufacturers)	marketed	Mood stabilizer	Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3	1970-04-06
Tegretol	carbamazepine	Novartis AG (originally Geigy)	marketed	Mood Stabilizer [EPC]	Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4	1968-03-11
CARBAMAZEPINE	CARBAMAZEPINE		marketed	Mood Stabilizer [EPC]		1968-01-01
Valproic acid, sodium salt	Valproic acid, sodium salt	Sanofi	marketed	Histone deacetylase inhibitor; anticonvulsant; mood stabilizer	Histone deacetylase (HDAC); GABA metabolism
Depakote (divalproate)	Depakote (divalproate)	Korea Otsuka Pharmaceutical Co., Ltd.	marketed	Anticonvulsant / Mood stabilizer	GABA metabolism; histone deacetylase inhibition
sodium valproate with Clozapine	sodium valproate with Clozapine	Shanghai Mental Health Center	marketed	Antipsychotic + mood stabilizer combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, GABA pathways, histone deacetylase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-11-10 — Tegretol · 9770407 · Formulation · US
2028-11-10 — Tegretol · 9629797 · Method of Use · US
2029-03-13 — Tegretol · 9750822 · Formulation · US
2029-03-13 — Tegretol · 7635773 · Formulation · US
2029-03-13 — Tegretol · 8410077 · Formulation · US
2033-02-27 — Tegretol · 9493582 · Formulation · US
2040-01-31 — Tegretol · 11529357 · Formulation · US

Sponsor landscape (Mood stabilizer class)

Shanghai Mental Health Center · 2 drugs in this class
Generic (multiple manufacturers) · 1 drug in this class
National Cheng-Kung University Hospital · 1 drug in this class
AstraZeneca · 1 drug in this class
University of Aarhus · 1 drug in this class
University of Milan · 1 drug in this class
Weill Medical College of Cornell University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lithium (LI) — Competitive Intelligence Brief. https://druglandscape.com/ci/lithium-li. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab